Home  |  Contact

UniProtKB/Swiss-Prot P00441: Variant p.Ile105Phe

Superoxide dismutase [Cu-Zn]
Gene: SOD1
Variant information

Variant position:  105
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Isoleucine (I) to Phenylalanine (F) at position 105 (I105F, p.Ile105Phe).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (I) to large size and aromatic (F)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Amyotrophic lateral sclerosis 1 (ALS1) [MIM:105400]: A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. {ECO:0000269|PubMed:10400992, ECO:0000269|PubMed:10430435, ECO:0000269|PubMed:10732812, ECO:0000269|PubMed:11369193, ECO:0000269|PubMed:11535232, ECO:0000269|PubMed:12145308, ECO:0000269|PubMed:12402272, ECO:0000269|PubMed:12754496, ECO:0000269|PubMed:12963370, ECO:0000269|PubMed:14506936, ECO:0000269|PubMed:15056757, ECO:0000269|PubMed:18301754, ECO:0000269|PubMed:18378676, ECO:0000269|PubMed:18552350, ECO:0000269|PubMed:19741096, ECO:0000269|PubMed:21220647, ECO:0000269|PubMed:21247266, ECO:0000269|PubMed:27604643, ECO:0000269|PubMed:7496169, ECO:0000269|PubMed:7501156, ECO:0000269|PubMed:7647793, ECO:0000269|PubMed:7655468, ECO:0000269|PubMed:7655469, ECO:0000269|PubMed:7655471, ECO:0000269|PubMed:7700376, ECO:0000269|PubMed:7795609, ECO:0000269|PubMed:7836951, ECO:0000269|PubMed:7870076, ECO:0000269|PubMed:7881433, ECO:0000269|PubMed:7887412, ECO:0000269|PubMed:7951252, ECO:0000269|PubMed:7980516, ECO:0000269|PubMed:7997024, ECO:0000269|PubMed:8069312, ECO:0000269|PubMed:8179602, ECO:0000269|PubMed:8351519, ECO:0000269|PubMed:8446170, ECO:0000269|PubMed:8528216, ECO:0000269|PubMed:8682505, ECO:0000269|PubMed:8907321, ECO:0000269|PubMed:8938700, ECO:0000269|PubMed:8990014, ECO:0000269|PubMed:9101297, ECO:0000269|PubMed:9131652, ECO:0000269|PubMed:9455977, ECO:0000269|PubMed:9541385}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In ALS1.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  105
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  154
The length of the canonical sequence.

Location on the sequence:   LGNVTADKDGVADVSIEDSV  I SLSGDHCIIGRTLVVHEKAD
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 154 Superoxide dismutase [Cu-Zn]
Metal binding 121 – 121 Copper; catalytic
Modified residue 92 – 92 N6-succinyllysine
Modified residue 99 – 99 Phosphoserine
Modified residue 103 – 103 Phosphoserine
Modified residue 106 – 106 Phosphoserine
Modified residue 108 – 108 Phosphoserine
Modified residue 123 – 123 N6-acetyllysine; alternate
Modified residue 123 – 123 N6-succinyllysine; alternate
Disulfide bond 58 – 147
Mutagenesis 112 – 112 C -> S. Enhances formation of fibrillar aggregates in the absence of bound zinc; when associated with S-7; S-58 and S-147.
Mutagenesis 123 – 123 K -> A. Decreased succinylation.
Mutagenesis 123 – 123 K -> E. Mimicks constitutive succinylation state; decreased activity.


Literature citations

Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene.
Ikeda M.; Abe K.; Aoki M.; Sahara M.; Watanabe M.; Shoji M.; St George-Hyslop P.H.; Hirai S.; Itoyama Y.;
Neurology 45:2038-2042(1995)
Cited for: VARIANT ALS1 PHE-105;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.